Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8993-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.86 million
Profitability
Miscellaneous
Employees37
OptionableOptionable
Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions
What is Vascular Biogenics' stock symbol?
Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
How were Vascular Biogenics' earnings last quarter?
Vascular Biogenics Ltd (NASDAQ:VBLT) posted its earnings results on Tuesday, November, 20th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.03. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.30 million. Vascular Biogenics had a negative net margin of 71.83% and a negative return on equity of 18.36%. View Vascular Biogenics' Earnings History.
When is Vascular Biogenics' next earnings date?
What price target have analysts set for VBLT?
4 equities research analysts have issued 12-month price targets for Vascular Biogenics' shares. Their predictions range from $3.00 to $4.00. On average, they expect Vascular Biogenics' share price to reach $3.3333 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.
What is the consensus analysts' recommendation for Vascular Biogenics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vascular Biogenics.
What are Wall Street analysts saying about Vascular Biogenics stock?
Here are some recent quotes from research analysts about Vascular Biogenics stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying a 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property." (1/15/2019)
- 2. Chardan Capital analysts commented, "We remain on the sidelines; ovarian cancer data in 4Q19 This morning, VBL Therapeutics reported 3Q18 results and provided updates on its programs. The company reported EPS of -$0.15, beating the Chardan estimate of -$0.20 by $0.05. With $53.7 mm in cash and cash equivalents as of 30 September 2018, VBL has sufficient cash to execute on its programs for at least the next three years." This should support the company through at least interim efficacy readout from the ongoing phase III OVAL study (NCT03398655) of its lead asset VB-111 in platinum- resistant ovarian cancer, anticipated in 4Q19, and the planned submission of IND filings for its MOSPD2 program in 2020. Implications for the OVAL trial in ovarian cancer are still unclear." (11/20/2018)
- 3. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (10/23/2018)
Has Vascular Biogenics been receiving favorable news coverage?
Press coverage about VBLT stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vascular Biogenics earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Who are some of Vascular Biogenics' key competitors?
Some companies that are related to Vascular Biogenics include Newron Pharmaceuticals (NWPHF), Aeglea Bio Therapeutics (AGLE), TAIWAN LIPOSOME/S (TLC), Aptinyx (APTX), Recro Pharma (REPH), Spero Therapeutics (SPRO), REDHILL BIOPHAR/S (RDHL), AcelRx Pharmaceuticals (ACRX), Protagonist Therapeutics (PTGX), Spring Bank Pharmaceuticals (SBPH), Molecular Templates (MTEM), Aquestive Therapeutics (AQST), ProMetic Life Sciences (PFSCF), Zafgen (ZFGN) and Nature's Sunshine Products (NATR).
Who are Vascular Biogenics' key executives?
Vascular Biogenics' management team includes the folowing people:
- Prof. Dror Harats, CEO & Director (Age 62)
- Mr. Amos Ron, CFO, Principal Accounting Officer & Company Sec. (Age 64)
- Dr. Erez Feige, VP of Bus. Operations (Age 45)
- Dr. Eyal Breitbart, VP of Research & Operations (Age 52)
- Dr. Naamit Sher, VP of Drug Devel. & Regulatory (Age 65)
Who are Vascular Biogenics' major shareholders?
Vascular Biogenics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CVI Holdings LLC (3.91%), RBF Capital LLC (1.01%) and Raymond James & Associates (0.15%).
Which major investors are selling Vascular Biogenics stock?
VBLT stock was sold by a variety of institutional investors in the last quarter, including CVI Holdings LLC and Raymond James & Associates.
Which major investors are buying Vascular Biogenics stock?
VBLT stock was purchased by a variety of institutional investors in the last quarter, including RBF Capital LLC.
How do I buy shares of Vascular Biogenics?
Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vascular Biogenics' stock price today?
One share of VBLT stock can currently be purchased for approximately $1.37.
How big of a company is Vascular Biogenics?
Vascular Biogenics has a market capitalization of $49.16 million and generates $13.86 million in revenue each year. The biopharmaceutical company earns $-10,130,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Vascular Biogenics employs 37 workers across the globe.
What is Vascular Biogenics' official website?
How can I contact Vascular Biogenics?
Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]
MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
